#1Proposed tier Unassignedlaboratory mechanisticAwaiting human appraisal
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
WPF seed · 2026 · PMID 41490200 · DOI 10.4155/fdd-2022-0009
laboratory-mechanistic
Scientific intelligence record
Experience 2.0
Synthetic regulatory peptide
Synthetic tuftsin-derived heptapeptide studied primarily in Russian-language preclinical and clinical literature.
Record status
Traceability partial
Last meaningful update: 9/20/2026
Ranked research corpus
116
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
116 matching records · ranked 2026-09-18
Page 1 of 5
WPF seed · 2026 · PMID 41490200 · DOI 10.4155/fdd-2022-0009
laboratory-mechanistic
Europe PMC · 2026 · PMID 41490200 · DOI 10.5435/jaaosglobal-d-25-00236
human-interventional
OpenAlex · 2026 · Source ID doi:10.1134/s002689332670007x · DOI 10.1134/s002689332670007x
preclinical-animal
OpenAlex · 2025 · Source ID doi:10.7868/s3034556125030113 · DOI 10.7868/s3034556125030113
preclinical-animal
OpenAlex · 2025 · Source ID doi:10.1134/s1819712425700783 · DOI 10.1134/s1819712425700783
preclinical-animal
OpenAlex · 2024 · Source ID doi:10.29296/25877305-2024-05-12 · DOI 10.29296/25877305-2024-05-12
contextual-unclassified
OpenAlex · 2024 · Source ID doi:10.22363/2313-0245-2024-28-1-256-264 · DOI 10.22363/2313-0245-2024-28-1-256-264
laboratory-mechanistic
OpenAlex · 2024 · Source ID doi:10.1134/s2635167624601335 · DOI 10.1134/s2635167624601335
preclinical-animal
OpenAlex · 2023 · Source ID doi:10.59315/jiscpp.2023-2-2.16-18 · DOI 10.59315/jiscpp.2023-2-2.16-18
laboratory-mechanistic
OpenAlex · 2023 · Source ID doi:10.1134/s1819712423020174 · DOI 10.1134/s1819712423020174
preclinical-animal
OpenAlex · 2023 · Source ID doi:10.31857/s1027813323020176 · DOI 10.31857/s1027813323020176
preclinical-animal
OpenAlex · 2023 · Source ID doi:10.21626/vestnik/2023-3/07 · DOI 10.21626/vestnik/2023-3/07
preclinical-animal
OpenAlex · 2023 · Source ID doi:10.59315/jiscpp.2023-2-1.46-48 · DOI 10.59315/jiscpp.2023-2-1.46-48
preclinical-animal
OpenAlex · 2022 · Source ID doi:10.37489/2587-7836-2022-1-30-35 · DOI 10.37489/2587-7836-2022-1-30-35
preclinical-animal
Europe PMC · 2022 · PMID 36322304 · DOI 10.1007/s10517-022-05624-x
preclinical-animal
OpenAlex · 2022 · Source ID doi:10.2478/afpuc-2022-0004 · DOI 10.2478/afpuc-2022-0004
contextual-unclassified
OpenAlex · 2022 · Source ID doi:10.47056/0365-9615-2022-173-6-714-718 · DOI 10.47056/0365-9615-2022-173-6-714-718
preclinical-animal
Europe PMC · 2021 · PMID 34396551 · DOI 10.1002/jcph.1922
preclinical-animal
WPF seed · 2021 · PMID 32621722 · DOI 10.2174/1574884715666200704152810
laboratory-mechanistic
OpenAlex · 2020 · Source ID doi:10.33667/2078-5631-2020-24-24-28 · DOI 10.33667/2078-5631-2020-24-24-28
contextual-unclassified
WPF seed · 2020 · PMID 32342318 · DOI 10.1134/S001249662001007X
laboratory-mechanistic
WPF seed · 2020 · PMID 32651826 · DOI 10.1007/s10517-020-04868-9
preclinical-animal
OpenAlex · 2020 · Source ID doi:10.1134/s1819712420030113 · DOI 10.1134/s1819712420030113
preclinical-animal
OpenAlex · 2020 · Source ID doi:10.15789/2220-7619-2019-5-6-805-810 · DOI 10.15789/2220-7619-2019-5-6-805-810
preclinical-animal
OpenAlex · 2020 · Source ID doi:10.19163/2307-9266-2019-7-6-321-331 · DOI 10.19163/2307-9266-2019-7-6-321-331
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review. 1 correction(s) have been recorded against this atlas's source metadata.
Selank evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Selank — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/selank
AMA / Vancouver
World Peptide Foundation. Selank — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/selank
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
4
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
28
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
116
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
4
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
28
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Selank no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasPubMed-indexed clinical trial; comparative study; journal article examining [a comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining therapeutic peptides in orthopaedics: applications, challenges, and future directions. Machine-staged source candidate; findings and limitations require accountable review before publication.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2003 · study · Temporal status not established
Neuroscience and behavioral physiology
2006 · study · Temporal status not established
Bioorganicheskaia khimiia
2008 · study · Temporal status not established
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2009 · study · Temporal status not established
Eksperimental'naia i klinicheskaia farmakologiia
2010 · study · Temporal status not established
Eksperimental'naia i klinicheskaia farmakologiia
2011 · study · Temporal status not established
Regulatory peptides
2013 · study · Temporal status not established
Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova
2014 · study · Temporal status not established
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2014 · study · Temporal status not established
Molecular immunology
2014 · study · Temporal status not established
Molekuliarnaia biologiia
2016 · study · Temporal status not established
Frontiers in pharmacology
2016 · study · Temporal status not established
Eksperimental'naia i klinicheskaia farmakologiia
2017 · study · Temporal status not established
Bulletin of experimental biology and medicine
2017 · study · Temporal status not established
Current medicinal chemistry
2017 · study · Temporal status not established
Bulletin of experimental biology and medicine
2017 · study · Temporal status not established
Bulletin of experimental biology and medicine
2017 · study · Temporal status not established
Behavioural neurology
2017 · study · Temporal status not established
Bulletin of experimental biology and medicine
2017 · study · Temporal status not established
Frontiers in pharmacology
2018 · study · Temporal status not established
Protein and peptide letters
2019 · study · Temporal status not established
Bulletin of experimental biology and medicine
2019 · study · Temporal status not established
Bulletin of experimental biology and medicine
2019 · study · Temporal status not established
Bulletin of experimental biology and medicine
2020 · study · Temporal status not established
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
2020 · study · Temporal status not established
Drug testing and analysis
2020 · study · Temporal status not established
Bulletin of experimental biology and medicine
2021 · study · Temporal status not established
Current reviews in clinical and experimental pharmacology
2026 · study · Temporal status not established
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
2026 · regulatory · Temporal status not established
European Union
2026 · regulatory · Temporal status not established
United States
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
7 represented evidence records
Years represented: 2006, 2008, 2017, 2019, 2020
Publishing organizations appearing in records: Bioorganicheskaia khimiia, Bulletin of experimental biology and medicine, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
6 represented evidence records
Years represented: 2011, 2014, 2016, 2017, 2018
Publishing organizations appearing in records: Behavioural neurology, Frontiers in pharmacology, Molecular immunology, Protein and peptide letters, Regulatory peptides
5 represented evidence records
Years represented: 2011, 2014, 2016, 2017
Publishing organizations appearing in records: Behavioural neurology, Frontiers in pharmacology, Molecular immunology, Regulatory peptides
5 represented evidence records
Years represented: 2011, 2014, 2016, 2017
Publishing organizations appearing in records: Behavioural neurology, Frontiers in pharmacology, Molecular immunology, Regulatory peptides
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 4 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Selank evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
United States
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:24:20 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
PubMed-indexed journal article examining anticoagulant effects of arginine-containing peptides of the glyproline family (his-phe-arg-trp-pro-gly-pro and thr-lys-pro-arg-pro-gly-pro) revealed by thromboelastography. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining functional connectomic approach to studying selank and semax effects. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining tuftsin - properties and analogs. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining the influence of selank on the level of cytokines under the conditions of "social" stress. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining the occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining [experimental optimization of learning and memory processes by selank]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article examining [immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining [transcriptome alteration in hippocampus under the treatment of tuftsin analog selank]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining selank administration affects the expression of some genes involved in gabaergic neurotransmission. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining the temporary dynamics of inflammation-related genes expression under tuftsin analog selank action. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article; research support, non-u.s. gov't examining the optimizing action of the synthetic peptide selank on a conditioned active avoidance reflex in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of bdnf content in the hippocampus and prefrontal cortex in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article examining [comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with pcpa]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed english abstract; journal article; research support, non-u.s. gov't examining [effect of tripeptide pro-gly-pro on rat brain transcriptome in focal ischemia]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining studying the toxic effects of some biologically active peptides on the model of mouse embryonic stem cells. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining state of colon microbiota in rats during chronic restraint stress and selank treatment. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining effect of selank on spontaneous synaptic activity of rat hippocampal ca1 neurons. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with selank. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article examining [comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to balb/c and c57bl/6 mice.]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining effect of selank on morphological parameters of rat liver in chronic foot-shock stress. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining expression of inflammation-related genes in mouse spleen under tuftsin analog selank. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining peptide selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining effect of selank on functional state of rat hepatocytes under conditions of restraint stress. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining gaba, selank, and olanzapine affect the expression of genes involved in gabaergic neurotransmission in imr-32 cells. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining [evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Machine-staged source candidate; findings and limitations require accountable review before publication.
5 represented evidence records
Years represented: 2011, 2014, 2016, 2017
Publishing organizations appearing in records: Behavioural neurology, Frontiers in pharmacology, Molecular immunology, Regulatory peptides
4 represented evidence records
Years represented: 2011, 2014, 2016, 2017
Publishing organizations appearing in records: Frontiers in pharmacology, Molecular immunology, Regulatory peptides
5 represented evidence records
Years represented: 2011, 2014, 2016, 2017
Publishing organizations appearing in records: Behavioural neurology, Frontiers in pharmacology, Molecular immunology, Regulatory peptides
4 represented evidence records
Years represented: 2017, 2019, 2020
Publishing organizations appearing in records: Bulletin of experimental biology and medicine
7 represented evidence records
Years represented: 2017, 2019, 2020
Publishing organizations appearing in records: Bulletin of experimental biology and medicine, Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
3 represented evidence records
Years represented: 2006, 2014, 2020
Publishing organizations appearing in records: Bioorganicheskaia khimiia, Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
3 represented evidence records
Years represented: 2006, 2008, 2014
Publishing organizations appearing in records: Bioorganicheskaia khimiia, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2 represented evidence records
Years represented: 2017, 2019
Publishing organizations appearing in records: Bulletin of experimental biology and medicine